Anoikis in Gastric Cancer: Mechanistic Insights Into Metastatic Survival and Therapeutic Targeting
Journal of Biochemical and Molecular Toxicology · 2026-11 · 40 (11)
DOI: 10.1002/jbt.71167 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 15.11.2026. Verfasst von Jian Zhong und 3 weiteren Autor:innen. Beteiligte Einrichtung: General Medicine Department, Ziyang Central Hospital, Ziyang, China. Hauptthemen laut MEDLINE: Anoikis, Stomach Neoplasms. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer (GC) remains a major cause of cancer‐related mortality worldwide, largely because many patients present with advanced or metastatic disease. Anoikis, a specialized form of detachment‐induced apoptosis, is a critical safeguard that eliminates epithelial cells after loss of appropriate extracellular matrix (ECM) and cell–cell adhesion; therefore, its disruption allows malignant cells to survive outside their native niche and acquire metastatic competence. In GC, anoikis resistance is central to tumor progression and peritoneal dissemination, enabling detached tumor cells to survive anchorage loss, mechanical stress, metabolic adaptation, and immune pressure before colonization. This review synthesizes current evidence on how anoikis is initiated, executed, and evaded in GC. Mechanistically, anoikis initiation begins with disruption of integrin–ECM and cadherin‐mediated adhesion, followed by focal adhesion remodeling, cytoskeletal reorganization, and suppression or rewiring of adhesion‐dependent survival signaling. Anoikis execution converges on mitochondrial and death‐receptor apoptotic pathways, including Bcl‐2 family regulation, caspase‐8/caspase‐9 activation, and executioner caspase cleavage. In contrast, anoikis evasion is driven by interconnected survival hubs, including integrin/FAK/Src, PI3K‐AKT, MEK‐ERK, NF‐κB, Wnt/β‐catenin, YAP/TEAD, BDNF/TrkB, and protective autophagy. GC‐specific mediators such as TCF7L2/PLAUR, MYH9/CTNNB1, ITGBL1/AKT/FBLN2, CAV1/epidermal growth factor receptor (EGFR)/ITGB1, GRP94/YAP–TEAD1, GDF15/autophagy, and TRIM69/PRKCD/BDNF further illustrate how detached GC cells acquire metastatic survival capacity. Translationally, these pathways provide a rationale for biomarker‐guided therapeutic strategies aimed at restoring anoikis sensitivity or disabling compensatory survival programs. Targeting anoikis resistance may therefore complement existing chemotherapy, targeted therapy, and immunotherapy approaches, particularly in GC subtypes characterized by peritoneal dissemination, EMT, YAP/TEAD activation, or integrin/PI3K‐AKT pathway dependence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General Medicine Department, Ziyang Central Hospital, Ziyang, China.
- Department of Gastroenterology, College of Clinical Medicine of Henan University of Science and Technology, luoyang, China.
- Intensive Care Unit, Ziyang Central Hospital, Ziyang, China.
ORCID-Profile: Honglei Wu
Zitieren
APA
Zhong, J., Qi, X., Wu, H., & Lei, Z. (2026). Anoikis in Gastric Cancer: Mechanistic Insights Into Metastatic Survival and Therapeutic Targeting. Journal of Biochemical and Molecular Toxicology, 40(11). https://doi.org/10.1002/jbt.71167
Vancouver
Zhong J, Qi X, Wu H, Lei Z. Anoikis in Gastric Cancer: Mechanistic Insights Into Metastatic Survival and Therapeutic Targeting. Journal of Biochemical and Molecular Toxicology. 2026;40(11). doi:10.1002/jbt.71167
BibTeX
@article{Zhong2026,
author = {Zhong, Jian and Qi, Xing and Wu, Honglei and Lei, Zheng},
title = {Anoikis in Gastric Cancer: Mechanistic Insights Into Metastatic Survival and Therapeutic Targeting},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {11},
doi = {10.1002/jbt.71167}
}
EUVIMED